SEC Form 4 · accession 0001237899-16-000094
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Neil Stahl
Officer — EVP Research and Development
Period of report
Dec 16, 2016
Accepted (ET)
Dec 20, 2016 · 4:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 19, 2016 | G | 1,500 | $0.00 | D | 40,470 | D | |
| Common Stock | Nov 7, 2016 | G | 7,876 | $0.00 | D | 23,950 | D | |
| Common Stock | holding | — | — | — | 10,000 | I | by GRAT | |
| Common Stock | holding | — | — | — | 5,000 | I | by GRAT | |
| Common Stock | holding | — | — | — | 5,621 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F1 | $381.92 | Dec 16, 2016 | A | 58,342 | A | — | Dec 16, 2026 | Common Stock | 58,342 | 58,342 | D |
Explanation of responses
- F1The stock option award vests in four equal annual installments, commencing one year after the date of grant.